CMS allows reimbursement for Spectrum cancer drug Zevalin
The CMS approved reimbursement for Spectrum Pharmaceuticals' non-Hodgkin's lymphoma drug Zevalin, effective Jan. 1. The ruling removes "a significant historical barrier" to use of the drug, CEO Rajesh Shrotriya said.
Reuters | 11/03
This story published in SNM SmartBrief on 11/05/2009
More from SmartBrief:
FDA approval expected for expanded use of Zevalin
Friday, September 4, 2009
FDA requests more data on non-Hodgkin's lymphoma drug Zevalin
Tuesday, July 7, 2009
FDA accepts more information on Spectrum's Zevalin
Tuesday, July 21, 2009
Get stories like these delivered daily for FREE:
|
SNM SmartBrief
Designed specifically for nuclear medicine and molecular imaging professionals, SNM SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession. Learn more |
|